Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT02636036 |
| Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors(SPICE) |
| completed |
| Phase 1 |
| 51 |
| Akamis BioINDUSTRY |
| 1 |
| Nov 9, 2021 |
| clinicaltrials |
| NCT01353625 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | completed | Phase 1 | 118 | CelgeneINDUSTRY | 4 | Oct 5, 2021 | clinicaltrials |
| NCT01816984 | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 12 | University of ChicagoOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT03022409 | A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). | completed | Phase 1 | 21 | AstraZenecaINDUSTRY | 3 | Aug 10, 2021 | clinicaltrials |
| NCT02544880 | PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC | completed | Phase 1 | 16 | Donald T. Weed, MD, FACSOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT02537223 | Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer | completed | Phase 1 | 9 | University Health Network, TorontoOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT03144778 | Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer | completed | Phase 1 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT01598077 | A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer | completed | Phase 1 | 54 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 19, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT04361409 | Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 10 | China Medical University HospitalOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT01254617 | Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer(ADCC) | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2020 | clinicaltrials |
| NCT01469429 | Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. | completed | Phase 1 / Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT03811652 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | completed | Phase 1 | 8 | MedImmune LLCINDUSTRY | 2 | Dec 30, 2019 | clinicaltrials |
| NCT02335918 | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 175 | Celldex TherapeuticsINDUSTRY | 1 | Dec 9, 2019 | clinicaltrials |
| NCT00257738 | 0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 | 17 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01758731 | Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History | completed | Phase 1 | 17 | University of Colorado, DenverOTHER | 1 | Sep 23, 2019 | clinicaltrials |
| NCT02473731 | A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients | completed | Phase 1 | 12 | Celldex TherapeuticsINDUSTRY | 1 | Aug 1, 2019 | clinicaltrials |
| NCT01064921 | Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma | completed | Phase 1 | 27 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT02069158 | Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor(IOSI-NDU-001) | completed | Phase 1 | 17 | Cristiana SessaOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT02277197 | Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | completed | Phase 1 | 14 | James J LeeOTHER | 1 | Apr 18, 2019 | clinicaltrials |
| NCT01716416 | Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)(HNSCC) | completed | Phase 1 | 32 | Washington University School of MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02565758 | ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors | completed | Phase 1 | 85 | AbbVieINDUSTRY | 3 | Apr 5, 2019 | clinicaltrials |
| NCT02508246 | WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 | 12 | University of WashingtonOTHER | 1 | Mar 13, 2019 | clinicaltrials |
| NCT00055913 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2018 | clinicaltrials |
| NCT02350712 | Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer | completed | Phase 1 | 15 | Daiichi SankyoINDUSTRY | 1 | Sep 11, 2018 | clinicaltrials |
| NCT02035527 | Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 | 3 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 24, 2018 | clinicaltrials |
| NCT01204099 | Study of PX-866 and Docetaxel in Solid Tumors | completed | Phase 1 / Phase 2 | 223 | Cascadian Therapeutics Inc.INDUSTRY | 2 | May 16, 2018 | clinicaltrials |
| NCT02216617 | Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy(TAPIS) | completed | Phase 1 | 8 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT02262741 | A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer | completed | Phase 1 | 71 | MedImmune LLCINDUSTRY | 2 | Oct 23, 2017 | clinicaltrials |
| NCT01727076 | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT01733823 | DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole | completed | Phase 1 / Phase 2 | 31 | Danish Head and Neck Cancer GroupNETWORK | 1 | Jul 28, 2017 | clinicaltrials |
| NCT00513383 | Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Mar 1, 2017 | clinicaltrials |
| NCT01921426 | A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck | completed | Phase 1 | 30 | Galera Therapeutics, Inc.INDUSTRY | 1 | Sep 22, 2016 | clinicaltrials |
| NCT01045421 | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies | completed | Phase 1 / Phase 2 | 273 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 15, 2016 | clinicaltrials |
| NCT01737008 | Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 | 12 | University Health Network, TorontoOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT01108042 | TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer | completed | Phase 1 / Phase 2 | 71 | Orlando Guntinas-Lichius, Prof. Dr. med.OTHER | 1 | May 18, 2016 | clinicaltrials |
| NCT00625456 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | completed | Phase 1 | 23 | Jennerex BiotherapeuticsINDUSTRY | 2 | Dec 3, 2015 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT01192204 | Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention | completed | Phase 1 / Phase 2 | 41 | Ohio State UniversityOTHER | 1 | Aug 14, 2015 | clinicaltrials |
| NCT01334177 | TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck | completed | Phase 1 | 13 | University of WashingtonOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT01379339 | Cabazitaxel - PF Induction Chemotherapy | completed | Phase 1 | 40 | Krzysztof MisiukiewiczOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00049283 | Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2014 | clinicaltrials |
| NCT00055770 | Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer | completed | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00049166 | Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00089362 | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Nov 22, 2021source: clinicaltrials